Injection site reactions on Zepbound (tirzepatide): Incidence, Severity, and Realistic Expectations

How often do injection site reactions happen on Zepbound?

The label's Table 1 pools two placebo-controlled weight-management trials, Study 1 and Study 2, in which 2,519 adults were treated with Zepbound for up to 72 weeks and 958 received placebo [1]. Injection site reactions were reported by 2% of the placebo group, 6% of the 5 mg group, and 8% of both the 10 mg and 15 mg groups [1].

Injection site reactions also appear in the label's list of adverse reactions reported in at least 5% of Zepbound-treated patients, alongside nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, fatigue, hypersensitivity reactions, eructation, hair loss and gastroesophageal reflux disease [1].

What the label counts as an injection site reaction

The footnote to that row says the number includes several related terms: injection site bruising, injection site erythema, injection site pruritus, injection site pain, injection site rash and injection site reaction [1]. Table 1 reports a single rate for all of them, so the 6% to 8% figure does not tell you which of those symptoms was most common [1].

How severe are these reactions?

A pooled analysis of seven phase 3 tirzepatide trials gives severity data. The analysis included 5,025 tirzepatide-treated adults with type 2 diabetes who were evaluable for antidrug antibodies [2]. More patients who developed treatment-emergent antibodies had hypersensitivity or injection site reactions than patients who did not, but most of those events were nonserious and nonsevere, and most occurred or resolved regardless of antibody status or titer [2]. The authors found no effect of antibodies on tirzepatide pharmacokinetics or efficacy [2].

The Zepbound label reports anti-tirzepatide antibodies in 64.5% of patients in the two weight-management trials, with no clinically significant effect on pharmacokinetics or effectiveness found [1].

Does the rate change with dose?

Moving from 5 mg to 10 mg took the reported rate from 6% to 8%, and 15 mg stayed at 8% [1]. The biggest step is the first one; the 10 mg and 15 mg groups were identical in the table.

Is it an allergic reaction or an ordinary site reaction?

Hypersensitivity reactions are a separate row in the same table, reported by 5% of patients on each Zepbound dose and 3% on placebo [1]. Severe hypersensitivity reactions occurred in 0.1% of Zepbound-treated patients and in no placebo-treated patients [1]. The label describes postmarketing reports of anaphylaxis and angioedema with tirzepatide, lists known serious hypersensitivity to tirzepatide or any excipient as a contraindication, and instructs patients who develop a hypersensitivity reaction to seek medical attention promptly and discontinue Zepbound [1].

Skin pain and allodynia

A 2026 case series described two adults with severe obesity treated with tirzepatide who developed moderate-to-severe cutaneous allodynia, meaning pain from a stimulus that does not normally cause pain, such as light touch [3]. In both patients the symptoms tracked with dose escalation and higher doses, and resolved after the drug was stopped [3]. The authors note that the U.S. prescribing information lists hypersensitivity and injection site reactions as its dermatologic adverse events and contains no reports of skin pain or allodynia [3].

What the label says about injecting

Approved sites are the abdomen, thigh and back of the upper arm, with the upper-arm site given by another person, and the label instructs patients to rotate sites [1]. Absorption is similar from all three sites [1]. Zepbound comes as a vial, a prefilled single-dose pen or a single-patient-use KwikPen, and each presentation needs its own training [1]. The Zepbound label says a KwikPen should not be shared between patients, even if the needle is changed, and that the KwikPen is not recommended for self-administration by people who are visually impaired [1].

Switching from another GLP-1

A retrospective chart review of 156 adults who changed from one incretin analog to another found that 7 did not tolerate the switch: 5 had gastrointestinal effects and 2 had injection site reactions [4]. The overall tolerability of the interchange was 96%, and the most common swaps were from dulaglutide to tirzepatide [4].